What's The BUZZ?

Market News, Products, Services, and Trends

Advertisement
Equashield Leaderboard Banner (December 2025)

Endo Launches Doxycycline for Injection, USP

Endo Launches Doxycycline for Injection, USP

MALVERN, Pa., Dec. 10, 2024 /PRNewswire/ — Endo, Inc. (OTCQX: NDOI) announced today that it has begun shipping doxycycline for injection, USP 100 mg/vial, an AP-rated version of DOXY 100™.


“We’re pleased to provide choices to healthcare providers and hospital pharmacies as they work to deliver quality patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “The doxycycline for injection strengthens our sterile injectable product portfolio and underscores our reputation as a reliable supplier of aseptic medicines.”


According to IQVIA®, doxycycline for injection 100 mg vial sales were approximately $49 million for the 12 months ended September 30, 2024.


DOXY 100™ is a trademark of Fresenius Kabi. Read more >

Par Health

Par Health News & Announcements

Par Health is a pharmaceutical company focused on Elevating the Essentials™. We develop, manufacture, and deliver high-quality generic medicines, active pharmaceutical ingredients (APIs) and sterile injectable products across a broad range of therapeutic areas, dosage forms and delivery technologies. With a vertically integrated, U.S.-advantaged manufacturing network and over 4,000 global employees, we are committed to reliability, integrity and operational excellence – because we believe great healthcare is built on getting the essentials right.

RXinsider Staff

Posted by: RXinsider Staff

RXinsider is a multimedia publishing and technology company offering print publications, digital platforms, events, and content creation services to the B2B pharmacy market.

SUBSCRIBE

Name
Subscription Choices
Checkboxes

Request information from Endo Launches Doxycycline for Injection, USP

Name
Address
Subscribe